Investigational drug · Phase 2
ARO-INHBE
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metabolic Dysfunction-Associated Steatohepatitis, Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "ARO-INHBE"
First trial start
2024
Dec 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ARO-INHBE", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metabolic Dysfunction-Associated Steatohepatitis
- Obesity
Approved drugs for the same conditions: Obesity and weight management · MASH (fatty liver disease) · Cardiovascular and metabolic · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ARO-INHBE" as an intervention, largest first.
- A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated SteatohepatitisPivotal-lookingNot yet recruiting
Arrowhead PharmaceuticalsIndustry
NCT07859813 · 252 participants (planned) · Start Sep 2026 · Primary completion Oct 2029
Drug: ARO-INHBE; Placebo · For: Metabolic Dysfunction-Associated Steatohepatitis
- A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusPivotal-lookingActive, not recruiting
Arrowhead PharmaceuticalsIndustry
NCT06700538 · 190 participants · Start Dec 4, 2024 · Primary completion Oct 15, 2027
Drug: ARO-INHBE; Placebo and 1 more · For: Obesity
Sites: Camberwell, Australia; Charlestown, Australia; Maroochydore, Australia · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metabolic Dysfunction-Associated Steatohepatitis
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- ALN-CIDEBPhase 34 trials
Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD
- ECC4703Phase 22 trials
Eccogene · Adult Obesity, Weight Management, Metabolic Dysfunction-associated Steatohepatitis
- ECC0509Phase 21 trial
Eccogene · Metabolic Dysfunction-associated Steatohepatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.